Title: U.S. Government Moves to Reclassify Cannabis, Paving the Way for Expanded Research and Financial Opportunities
On Thursday, the Trump administration announced a significant shift in the federal classification of cannabis, a move that could greatly enhance scientific research into its medical applications. While this reclassification will not legalize cannabis at the federal level, it will transition the substance from a Schedule I to a Schedule III classification under the U.S. Drug Enforcement Administration (DEA).
In an official statement, the Department of Justice (DOJ) indicated that it will immediately reclassify FDA-approved products containing marijuana and items regulated under state medical marijuana licenses to Schedule III. Additionally, the DOJ has scheduled an expedited hearing for June to formally consider the reclassification of cannabis at the federal level.
“This initiative provides immediate and long-term clarity to researchers, patients, and providers while maintaining strict federal controls against illicit drug trafficking,” the DOJ stated.
Currently, substances classified as Schedule I, including heroin and LSD, are deemed to have no accepted medical use and exhibit a high potential for abuse. In contrast, Schedule III substances, such as Tylenol with codeine and testosterone, are recognized for their medical benefits and face fewer regulatory restrictions.
The reclassification of cannabis is expected to lower the barriers that have historically obstructed research into its therapeutic uses. This change could significantly impact the cannabis industry by exempting companies from IRS Code Section 280E, which has previously prevented them from deducting standard business expenses like rent and payroll. Moreover, it opens avenues for banking access that have been largely unavailable until now.
Despite these potential benefits, investor reactions have been mixed, with cannabis stocks experiencing a pullback after initial gains. Critics have raised concerns about the possibility of a bifurcated drug development system, where developers might circumvent the FDA process in favor of state-level pathways.
Nonetheless, this reclassification represents one of the most substantial shifts in federal marijuana policy in decades, indicating a growing willingness in Washington to reevaluate the categorization and study of cannabis in the United States.
Companies such as Tilray, which is known for its recreational cannabis products, may stand to gain from this policy change. Tilray has been expanding its medical segment, serving hundreds of thousands of patients across more than 20 countries. CEO Irwin Simon expressed optimism about potential partnerships with pharmaceutical companies, drawing parallels to the outreach alcohol companies initiated following increased demand for hemp-derived beverages.
Researchers have long faced rigorous approval processes, limited access to supplies, and extensive compliance requirements when investigating cannabis for therapeutic applications, including chronic pain, PTSD, and neurological disorders. These federal barriers have remained intact even as nearly half of U.S. states have legalized marijuana for recreational use, with even more approving its medical use.
Wendy Bronfein, co-founder and chief brand officer at Curio Wellness, a Maryland-based cannabis company, noted that while operators would still encounter a fragmented state-by-state system, the improved cash flow resulting from reclassification would bolster reinvestment and stability, ultimately fostering more consistent industry standards over time.
This recent decision follows an executive order issued last year that directed federal agencies to initiate the reclassification process, which typically involves scientific review, interagency coordination, and rulemaking procedures. Shawn Hauser, a partner at cannabis law firm Vicente LLP, emphasized that this rescheduling is not the conclusion but rather a critical phase in a long-running effort for cannabis reform.
The Biden administration had begun the reclassification process in 2024, which included a 60-day public comment period. However, subsequent hearings to address potential obstacles were delayed during the transition between administrations.
This announcement comes shortly after President Trump signed an executive order on psychedelics aimed at accelerating research and clinical trials for substances like psilocybin, MDMA, and ibogaine, further signaling a shift in federal attitudes toward controlled substances.
